Roche News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

05.11.24	Roche to present new and encouraging long-term follow-up data across broad haematology portfolio at ASH 2024 (Roche Holding AG)
31.10.24	Roche presents new data at CTAD, demonstrating its growing momentum in diagnostics for Alzheimer’s disease (Roche Holding AG)
31.10.24	New England Journal of Medicine publishes landmark phase III results for Roche’s Itovebi, showing more than doubling of progression-free survival in certain type of HR-positive advanced breast cancer (Roche Holding AG)
23.10.24	[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong sales growth of 9% (CER) continues in the third quarter of 2024; Group sales increase 6% in the first nine months (Roche Holding AG)
18.10.24	Roche’s Vabysmo improved vision in underrepresented populations with diabetic macular edema (DME) in a first-of-its-kind study (Roche Holding AG)
14.10.24	Majority of children with spinal muscular atrophy (SMA) treated with Roche’s Evrysdi are able to sit, stand and walk independently, two-year data demonstrate (Roche Holding AG)
11.10.24	FDA approves Roche’s Itovebi, a targeted treatment for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation (Roche Holding AG)
10.10.24	Roche obtains CE certification for the first companion diagnostic to identify patients with gastric and gastroesophageal junction cancer eligible for targeted treatment with VYLOY (Roche Holding AG)
26.09.24	Positive phase III results for Roche’s Gazyva/Gazyvaro show superiority to standard therapy alone in people with lupus nephritis (Roche Holding AG)
24.09.24	Roche launches the first test to use its breakthrough TAGS technology for high throughput, simultaneous detection of 12 respiratory viruses (Roche Holding AG)
23.09.24	WHO endorses dual-stain cytology (CINtec PLUS) testing in its cervical cancer prevention guidelines, advancing patient care and underlining Roche’s role in pioneering cervical cancer solutions (Roche Holding AG)
19.09.24	Positive phase III results show Xofluza significantly reduces the transmission of influenza viruses (Roche Holding AG)
16.09.24	FDA approves OCREVUS ZUNOVO™ as the first and only twice-a-year 10-minute subcutaneous injection for people with relapsing and progressive multiple sclerosis (Roche Holding AG)
13.09.24	FDA approves Roche’s Tecentriq Hybreza, the first and only subcutaneous anti-PD-(L)1 cancer immunotherapy (Roche Holding AG)
10.09.24	Roche opens Pharma Research and Development Center in Basel to accelerate scientific innovation (Roche Holding AG)
04.09.24	Roche’s fenebrutinib demonstrated near-complete suppression of disease activity and disability progression for up to 48 weeks in patients with relapsing multiple sclerosis (Roche Holding AG)
27.08.24	Roche’s PiaSky approved in the EU as the first monthly subcutaneous treatment for people with PNH (Roche Holding AG)
20.08.24	Roche responds to WHO’s declaration of a global health emergency due to the ongoing mpox outbreak (Roche Holding AG)
30.07.24	European Commission approves Roche’s Vabysmo for treatment of retinal vein occlusion (RVO) (Roche Holding AG)
29.07.24	Roche closes acquisition of LumiraDx’s Point of Care technology to expand access to diagnostic testing in primary care (Roche Holding AG)
25.07.24	[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 5% (CER) in first half of 2024; strong growth in second quarter - full-year earnings outlook raised (Roche Holding AG)
18.07.24	New data for Roche’s Susvimo demonstrates sustained efficacy in two serious diabetic eye conditions (Roche Holding AG)
17.07.24	Roche’s Vabysmo showed extended durability, continued efficacy and a consistent safety profile in long-term diabetic macular edema (DME) study (Roche Holding AG)
17.07.24	[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment of people with obesity (Roche Holding AG)
09.07.24	Roche receives CE Mark for its AI-enabled continuous glucose monitoring solution offering critical predictions to people living with diabetes (Roche Holding AG)
08.07.24	Roche to reintroduce Susvimo in the US for people with neovascular age-related macular degeneration (nAMD) (Roche Holding AG)
05.07.24	FDA approves Roche’s Vabysmo prefilled syringe (PFS) for three leading causes of vision loss (Roche Holding AG)
04.07.24	[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on phase II/III SKYSCRAPER-06 study in metastatic non-squamous non-small cell lung cancer (Roche Holding AG)
28.06.24	Roche’s Vabysmo gets CHMP recommendation for third indication retinal vein occlusion (RVO) (Roche Holding AG)
28.06.24	CHMP recommends EU approval of Roche’s PiaSky for people with PNH, a rare, life-threatening blood condition (Roche Holding AG)
27.06.24	Roche expands access to cervical cancer screening tools with two new WHO prequalification designations, including HPV self-collection (Roche Holding AG)
25.06.24	Roche’s OCREVUS subcutaneous administration approved by European Commission, as first and only twice-a-year injection for relapsing and primary progressive multiple sclerosis (Roche Holding AG)
24.06.24	Roche launches new analytical units for cobas® pro integrated solutions delivering greater efficiency and capacity to laboratories (Roche Holding AG)
20.06.24	Roche launches new highly-sensitive test to more easily diagnose patients who may have B-cell lymphoma (Roche Holding AG)
15.06.24	Roche’s Phase III STARGLO study demonstrates Columvi significantly extends survival in people with relapsed or refractory diffuse large B-cell lymphoma (Roche Holding AG)
10.06.24	Roche four-in-one molecular test for SARS-CoV-2, Influenza A/B viruses and RSV receives U.S. FDA Emergency Use Authorization (Roche Holding AG)
10.06.24	European Commission approves Roche’s Alecensa as the first and only targeted adjuvant treatment for people with ALK-positive early-stage lung cancer (Roche Holding AG)
07.06.24	Five-year data for Roche’s Evrysdi show the majority of treated children with a severe form of spinal muscular atrophy (SMA) achieved or maintained the ability to sit, stand or walk (Roche Holding AG)
29.05.24	FDA grants Priority Review to Roche’s inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation (Roche Holding AG)
27.05.24	Changes to the Roche Enlarged Corporate Executive Committee (Roche Holding AG)
22.05.24	Roche granted FDA Breakthrough Device Designation for blood test measuring Lp(a) - a key marker for hereditary cardiovascular risk (Roche Holding AG)
21.05.24	FDA grants Breakthrough Therapy Designation to Roche’s inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation (Roche Holding AG)
16.05.24	[Ad hoc announcement pursuant to Art. 53 LR] Roche reports positive Phase Ib results for its dual GLP-1/GIP receptor agonist CT-388 in people with obesity (Roche Holding AG)
15.05.24	Roche announces FDA approval of one of the first HPV self-collection solutions in the U.S., expanding access and screening options to help eliminate cervical cancer (Roche Holding AG)
24.04.24	[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 2% (CER) in first quarter with both divisions growing in high single digit ex COVID-19 (Roche Holding AG)
19.04.24	FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer (Roche Holding AG)
17.04.24	Roche’s subcutaneous OCREVUS one-year data demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS (Roche Holding AG)
15.04.24	[Ad hoc announcement pursuant to Art. 53 LR] Roche’s Columvi meets primary endpoint of overall survival in people with relapsed or refractory diffuse large B-cell lymphoma in Phase III STARGLO study (Roche Holding AG)
11.04.24	Roche granted FDA Breakthrough Device Designation for blood test to support earlier Alzheimer's disease diagnosis (Roche Holding AG)
26.03.24	Roche receives FDA approval for the first molecular test to screen for malaria in blood donors (Roche Holding AG)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

11:35		Roche-Aktie stabil: Swissmedic genehmigt subkutane Version von Ocrevus
11:29		Novartis-Aktie wenig bewegt: Novartis passt Umsatzziele nach oben an
11:28		Goldman Sachs Group Inc. veröffentlicht Investment-Empfehlung: Novartis-Aktie mit Neutral
09:54		Investment-Tipp: So bewertet Barclays Capital die Novartis-Aktie
09:33		Novartis-Analyse: JP Morgan Chase & Co. vergibt Neutral an Novartis-Aktie
09:28		Zurückhaltung in Zürich: SMI zum Handelsstart im Minus
09:28		Schwacher Handel in Zürich: SLI sackt zum Handelsstart ab

11:35

Roche-Aktie stabil: Swissmedic genehmigt subkutane Version von Ocrevus

11:29

Novartis-Aktie wenig bewegt: Novartis passt Umsatzziele nach oben an

11:28

Goldman Sachs Group Inc. veröffentlicht Investment-Empfehlung: Novartis-Aktie mit Neutral

09:54

Investment-Tipp: So bewertet Barclays Capital die Novartis-Aktie

09:33

Novartis-Analyse: JP Morgan Chase & Co. vergibt Neutral an Novartis-Aktie

09:28

Zurückhaltung in Zürich: SMI zum Handelsstart im Minus

09:28

Schwacher Handel in Zürich: SLI sackt zum Handelsstart ab

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Zurich Insur Gr	542.80	2.22 %	K V
Logitech Intl	69.34	1.23 %	K V
Swiss Re	127.05	0.87 %	K V
Roche Hldg G	250.50	0.52 %	K V
Givaudan	3’879.00	0.41 %	K V
Nestle	75.98	-0.71 %	K V
Kuehne+Nagel Int	206.70	-0.72 %	K V
Part Grp Hldg	1’209.50	-0.86 %	K V
Sonova Hldg	299.90	-1.15 %	K V
CieFinRichemont	116.95	-1.39 %	K V

Nachrichten zu Roche AG (Genussschein)

Aktien Top/Flop

Roche Peer Group Nachrichten

Meistgelesene Nachrichten